orfiril retard 300 mg
desitin arzneimittel gmbh - natriumvalproat - depottablett - 300 mg
zoledronsyre fresenius kabi 4 mg/5 ml
fresenius kabi norge as - halden - zoledronsyremonohydrat - konsentrat til infusjonsvæske, oppløsning - 4 mg/5 ml
zoledo 4 mg/100 ml
accord healthcare b.v. - zoledronsyre - infusjonsvæske, oppløsning - 4 mg/100 ml
zoledronic acid oresund pharma 4 mg/100 ml
oresund pharma aps - zoledronsyremonohydrat - infusjonsvæske, oppløsning - 4 mg/100 ml
faslodex
astrazeneca ab - fulvestrant - bryst neoplasms - endokrin terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausal women, kombinert behandling med palbociclib bør kombineres med en luteiniserende hormon-frigjørende hormon (lhrh) agonist.
fulvestrant medical valley 250 mg
medical valley invest ab - fulvestrant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 250 mg
faslodex 250 mg/5 ml
paranova as (1) - fulvestrant - injeksjonsvæske, oppløsning - 250 mg/5 ml
fulvestrant sun 250 mg
sun pharmaceutical - nederland - fulvestrant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 250 mg
fulvestrant accord 250 mg
accord healthcare b.v. - fulvestrant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 250 mg
fulvestrant ever pharma 250 mg
ever valinject gmbh - fulvestrant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 250 mg